The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe Cleveland Clinic
About this trial
The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are:
* Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation? * Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication? * Are there any differences in the rates of complications gastric aspiration in patients who hold vs. continue a single dose of their GLP-1 or GIP agonist medication?
Eligibility criteria
Qualifiers
Adult patient (Age 18 years or older)
Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy
Using a GLP-1 or GIP agonist at a stable dose for at least one month
Disqualifiers
Unable to provide informed consent, e.g., dementia
Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy)
Cirrhosis
Parkinson's disease
Trial design
Treatments tested in this trial
- Continue GLP/GIP
Treatment groups
132 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov